Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients

Launched by MEDICAL UNIVERSITY OF VIENNA · Apr 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a specific blood test, called anti-factor Xa activity (antiXa), relates to blood clots in critically ill patients in the intensive care unit (ICU). The researchers want to understand if levels of antiXa are linked to the occurrence of venous thromboembolism (VTE), which includes conditions like deep vein thrombosis and pulmonary embolism. They will also look at how the blood thinner enoxaparin affects antiXa levels and whether there are any bleeding complications related to it. Additionally, they want to find out how often VTE happens in ICU patients and how it impacts important outcomes like survival, quality of life, and hospital stay.

To participate in this study, individuals need to be at least 18 years old and have been admitted to an ICU within the last 24 hours, with plans to stay for more than 48 hours. However, those currently receiving specific types of blood thinners, having certain medical conditions, or with a very limited life expectancy are not eligible. Participants can expect to have their antiXa levels tested during their hospital stay, and the findings may help improve care for future patients in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 18 years at the time of intensive care unit admission
• • Admission to a participating intensive care unit within the last 24 hours
• • Expected discharge is later than 48 hours after enrolment
• Exclusion Criteria:
• • Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE/kg when given twice daily or of at least 150 IE/kg when given once daily
• • Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment
• • Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period
• • Estimated life expectancy below 48 hours or comfort terminal care order in place
• • Previously diagnosed heparin-induced thrombocytopenia
• • Pre-operative admission for elective surgery
• • Previous enrolment in the study